128 related articles for article (PubMed ID: 19487289)
1. AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects.
Davies NJ; Hayden RE; Simpson PJ; Birtwistle J; Mayer K; Ride JP; Bunce CM
Cancer Res; 2009 Jun; 69(11):4769-75. PubMed ID: 19487289
[TBL] [Abstract][Full Text] [Related]
2. New enzymatic assay for the AKR1C enzymes.
Beranič N; Stefane B; Brus B; Gobec S; Rižner TL
Chem Biol Interact; 2013 Feb; 202(1-3):204-9. PubMed ID: 23261716
[TBL] [Abstract][Full Text] [Related]
3. Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria.
Rotem R; Heyfets A; Fingrut O; Blickstein D; Shaklai M; Flescher E
Cancer Res; 2005 Mar; 65(5):1984-93. PubMed ID: 15753398
[TBL] [Abstract][Full Text] [Related]
4. Methyl jasmonate: a plant stress hormone as an anti-cancer drug.
Cohen S; Flescher E
Phytochemistry; 2009 Sep; 70(13-14):1600-9. PubMed ID: 19660769
[TBL] [Abstract][Full Text] [Related]
5. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
[TBL] [Abstract][Full Text] [Related]
6. Aldo-keto reductase 1C subfamily genes in skin are UV-inducible: possible role in keratinocytes survival.
Marín YE; Seiberg M; Lin CB
Exp Dermatol; 2009 Jul; 18(7):611-8. PubMed ID: 19320734
[TBL] [Abstract][Full Text] [Related]
7. Ruthenium complexes as inhibitors of the aldo-keto reductases AKR1C1-1C3.
Traven K; Sinreih M; Stojan J; Seršen S; Kljun J; Bezenšek J; Stanovnik B; Turel I; Rižner TL
Chem Biol Interact; 2015 Jun; 234():349-59. PubMed ID: 25446855
[TBL] [Abstract][Full Text] [Related]
8. Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily.
Ruiz FX; Porté S; Gallego O; Moro A; Ardèvol A; Del Río-Espínola A; Rovira C; Farrés J; Parés X
Biochem J; 2011 Dec; 440(3):335-44. PubMed ID: 21851338
[TBL] [Abstract][Full Text] [Related]
9. N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3.
Sinreih M; Sosič I; Beranič N; Turk S; Adeniji AO; Penning TM; Rižner TL; Gobec S
Bioorg Med Chem Lett; 2012 Sep; 22(18):5948-51. PubMed ID: 22897946
[TBL] [Abstract][Full Text] [Related]
10. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase.
Goldin N; Arzoine L; Heyfets A; Israelson A; Zaslavsky Z; Bravman T; Bronner V; Notcovich A; Shoshan-Barmatz V; Flescher E
Oncogene; 2008 Aug; 27(34):4636-43. PubMed ID: 18408762
[TBL] [Abstract][Full Text] [Related]
11. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
12. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes.
Bauman DR; Rudnick SI; Szewczuk LM; Jin Y; Gopishetty S; Penning TM
Mol Pharmacol; 2005 Jan; 67(1):60-8. PubMed ID: 15475569
[TBL] [Abstract][Full Text] [Related]
13. The anti-cancer activities of jasmonates.
Raviv Z; Cohen S; Reischer-Pelech D
Cancer Chemother Pharmacol; 2013 Feb; 71(2):275-85. PubMed ID: 23196641
[TBL] [Abstract][Full Text] [Related]
14. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.
Khanim F; Davies N; Veliça P; Hayden R; Ride J; Pararasa C; Chong MG; Gunther U; Veerapen N; Winn P; Farmer R; Trivier E; Rigoreau L; Drayson M; Bunce C
Br J Cancer; 2014 Mar; 110(6):1506-16. PubMed ID: 24569460
[TBL] [Abstract][Full Text] [Related]
15. Jasmonates in cancer therapy.
Flescher E
Cancer Lett; 2007 Jan; 245(1-2):1-10. PubMed ID: 16600475
[TBL] [Abstract][Full Text] [Related]
16. Natural jasmonates of different structures suppress the growth of human neuroblastoma cell line SH-SY5Y and its mechanisms.
Tong QS; Jiang GS; Zheng LD; Tang ST; Cai JB; Liu Y; Zeng FQ; Dong JH
Acta Pharmacol Sin; 2008 Jul; 29(7):861-9. PubMed ID: 18565287
[TBL] [Abstract][Full Text] [Related]
17. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
Beranič N; Gobec S; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
[TBL] [Abstract][Full Text] [Related]
18. Jasmonates induce nonapoptotic death in high-resistance mutant p53-expressing B-lymphoma cells.
Fingrut O; Reischer D; Rotem R; Goldin N; Altboum I; Zan-Bar I; Flescher E
Br J Pharmacol; 2005 Nov; 146(6):800-8. PubMed ID: 16170329
[TBL] [Abstract][Full Text] [Related]
19. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis.
Birtwistle J; Hayden RE; Khanim FL; Green RM; Pearce C; Davies NJ; Wake N; Schrewe H; Ride JP; Chipman JK; Bunce CM
Mutat Res; 2009 Mar; 662(1-2):67-74. PubMed ID: 19162045
[TBL] [Abstract][Full Text] [Related]
20. Jasmonates--a new family of anti-cancer agents.
Flescher E
Anticancer Drugs; 2005 Oct; 16(9):911-6. PubMed ID: 16162967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
